Drugs / Replens
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03185169 | Nov 2016 → Jul 2018 | female breast carcinoma, urinary tract infection, urogenital tract malformation, vaginal disorder | Alta Bates Summit Medical Center | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01984138 Comparator | Sep 2013 → Jun 2025 overdue | estrogen-receptor positive breast cancer | Polly A. Niravath, MD | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Replens | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01984138 ↗ |